

Emtricitabine/Tenofovir disoproxil Krka for PrEP - Reminder card

You have been prescribed Emtricitabine/Tenofovir disoproxil Krka for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. In order for this medicine to work effectively it is important that you don't miss or skip doses.

One tablet of Emtricitabine/Tenofovir disoproxil Krka should be taken every day, at the same time of day, preferably with food. Take Emtricitabine/Tenofovir disoproxil Krka exactly as your doctor has told you.

It is helpful to make taking medication part of your routine, for example taking it with your lunch, or when you brush your teeth after breakfast. It is important to find a time that works for you.

You can also use a small weekly pill box and put in the necessary tablets every week.

You might find it helpful to use the calendar to tick off each day. Starting in your first week, tick the day when you start Emtricitabine/Tenofovir disoproxil Krka, then tick the relevant box every day as you take your medicine.

After 30 days (one bottle of tablets), you will need to start a new calendar.

		Sun	Mon	Tue	Wed	Thu	Fri	Sat
Start here	Week 1							
	Week 2							
	Week 3							
	Week 4							
	Week 5							
	Week 6							

If you already use a calendar on your phone or PC, you could add a daily reminder for your Emtricitabine/Tenofovir disoproxil Krka.

DATE WHEN YOU TOOK THE FIRST EMTRICITABINE/TENOFOVIR DISOPROSTIL KRKA FROM A NEW BOTTLE (DAY/MONTH/YEAR):

Date of preparation: December 2019



Appointment Reminder

Your next clinic appointment is:

Appointment	Date	Time	Location

Reporting of side effects

If you get side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the patient information leaflet. You can also report side effects directly via the national reporting system:

HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, e-mail: medsafety@hpra.ie

Any suspected adverse reactions can also be reported to Krka, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto; Tel: +386 7 331 21 11 and +386 1 47 51 100; Website: www.krka.si; Email: pharmacovigilance@krka.biz